Pharmacogenetics of Ace Inhibitor-Associated Angioedema:Aim 1.

Trial Profile

Pharmacogenetics of Ace Inhibitor-Associated Angioedema:Aim 1.

Completed
Phase of Trial: Phase IV

Latest Information Update: 15 Dec 2016

At a glance

  • Drugs Sitagliptin (Primary) ; Enalaprilat
  • Indications Hypertension; Type 2 diabetes mellitus
  • Focus Pharmacodynamics
  • Acronyms Aim-1
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 12 Oct 2015 Status changed from recruiting to completed.
    • 17 Jun 2013 Planned end date changed from 1 May 2015 to 1 May 2014 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top